Previous Section
Review Articles
41. Clinical relevance of cytogenetics in myelodysplastic syndromes.
- Author
- Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M;
- Institution
- Department of Blood, Heart and Lung Medical Sciences of the University of Pavia and Division of Hematology, Fondazione Policlinico San Matteo IRCCS, Pavia, Italy. p.bernasconi@smatteo.pv.it
- Journal
- Ann N Y Acad Sci. 2006 Nov;1089:395-410.
- Abstract URL
- Click here to view abstract
42. Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes.
- Author
- Cilloni D; Messa E; Messa F; Carturan S; Defilippi I; Arruga F; Rosso V; Catalano R; Bracco E; Nicoli P; Saglio G;
- Institution
- Department of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano-Torino, Italy. daniela.cilloni@unito.it
- Journal
- Ann N Y Acad Sci. 2006 Nov;1089:411-23.
- Abstract URL
- Click here to view abstract
43. Immunomodulation in myelodysplastic syndromes.
- Author
- Sekeres MA; List A;
- Institution
- Cleveland Clinic Lerner College of Medicine, Department of Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic Foundation, Desk R35, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. sekerem@ccf.org
- Journal
- Best Pract Res Clin Haematol. 2006;19(4):757-67.
- Abstract URL
- Click here to view abstract
44. Advances in erythropoietic growth factor therapy for myelodysplastic syndromes.
- Author
- Mundle SD;
- Institution
- Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA. smundle@obius.jnj.com
- Journal
- Expert Opin Biol Ther. 2006 Nov;6(11):1099-104.
- Abstract URL
- Click here to view abstract
45. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches.
- Author
- Deschler B; de Witte T; Mertelsmann R; Lubbert M; Deschler B; de Witte T; Mertelsmann R; Lubbert M;
- Institution
- Department of Hematology Oncology, University of Freiburg Hugstetterstr. 55, D-79106 Freiburg, Germany.
- Journal
- Haematologica. 2006 Nov;91(11):1513-22.
- Abstract URL
- Click here to view abstract
46. The role of decitabine in the treatment of myelodysplastic syndromes.
- Author
- Atallah E; Kantarjian H; Garcia-Manero G;
- Institution
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Journal
- Expert Opin Pharmacother. 2007 Jan;8(1):65-73.
- Abstract URL
- Click here to view abstract
47. Drug insight: emerging new drugs in the treatment of myelodysplastic syndromes.
- Author
- Faderl, Stefan; Kantarjian, Hagop M;
- Institution
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. sfaderl@mdanderson.org
- Journal
- Nat Clin Pract Oncol 2005 Jul;2(7):348-55.
- Abstract URL
- Click here to view abstract
48. Azacitidine.
- Author
- Issa, Jean-Pierre; Kantarjian, Hagop;
- Institution
- Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston 77030, USA. jpissa@mdanderson.org
- Journal
- Nat Rev Drug Discov 2005 May;Suppl:S6-7.
- Abstract URL
- Click here to view abstract
